Gerresheimer has recorded a consolidated net loss of €318.7m in financial year 2025, versus adjusted net income of €84.3m a year earlier.
The medical and cosmetic packaging maker’s result was affected by non-cash depreciation, amortisation and impairments of around €521.5m, along with exceptional charges including restructuring costs of approximately €71.8m.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The impairments were mainly linked to technology and development projects at Sensile Medical, goodwill, and the assets of Gerresheimer Moulded Glass Chicago in the US.
Group revenue increased by 16.6% to €2.3bn from €1.9bn in 2024 on an adjusted basis, reflecting the first-time consolidation of Bormioli Pharma.
Adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) came to €384m, against an adjusted figure of €388m in the previous year.
As a result of the negative consolidated net income, which is partly reflected in the separate financial statements of Gerresheimer, no dividend will be paid for 2025.
Underlying growth was led mainly by the Plastics & Devices unit, especially through demand for drug delivery devices.
In contrast, the Primary Packaging Glass unit faced weaker demand for packaging used in cosmetics and pharmaceutical oral liquids.
Revenue in Plastics & Devices was €1.3bn in 2025, compared with €1.2bn in 2024 on an adjusted, pro-forma basis. Bormioli Pharma accounted for around €167m of that figure.
Primary Packaging Glass posted revenue of €983.5m, down from €1.052bn in 2024 on an adjusted, pro-forma basis. Bormioli Pharma contributed €168m to that total.
For the 2026 financial year, the company expects revenue in the lower half of the €2.3bn–2.4bn range and an adjusted EBITDA margin of 17–18%.
Gerresheimer said the sale process for Centor is moving forward and it expects to complete the transaction before the end of this year.
It added that proceeds from the disposal, together with debt refinancing planned for this year, should improve its financial position.
Gerresheimer chief financial officer Wolf Lehmann said: “The publication of the audited 2025 annual and consolidated financial statements sends an important positive signal to our customers, financing partners and investors.
“Transparency and compliance are our top priorities. We have thoroughly reviewed the issues and reflected them in the financial statements. With the sale of our US subsidiary Centor proceeding well, the planned refinancing and the continued consistent implementation of our transformation programme, we will also be improving our financial situation step by step in the coming months.”
Notably, in April, Gerresheimer rejected a takeover proposal from US-based Silgan, as per a report by Reuters.
